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Objective: This study was undertaken to determine the association between amio-
darone therapy and risk of complications of cardiac surgery in patients in the
randomized placebo-controlled, double-blind Canadian Amiodarone Myocardial
Infarction Arrhythmia Trial.
Methods: Prospectively collected data regarding postoperative complications in 82
patients who underwent cardiac surgery during Canadian Amiodarone Myocardial
Infarction Arrhythmia Trial participation were analyzed; 36 patients were randomly
assigned to receive amiodarone and 46 were assigned to receive placebo. Of the
patients randomly assigned to receive amiodarone, 24 patients continued amioda-
rone treatment to within 7 days of the operation (active amiodarone group) and 12
patients had the amiodarone discontinued at least 7 days before the operation
(discontinued amiodarone group).
Results: The baseline characteristics of the three groups were similar. The risks of
ventricular fibrillation, atrial fibrillation, and respiratory complications were similar.
The risk of requiring an intra-aortic balloon pump was significantly increased by
amiodarone (34.8% vs 16.7% vs 8.7% for active amiodarone, discontinued amio-
darone, and placebo groups, respectively, P  .024). There was no significant
difference in the use of temporary pacing. Neither the mean duration of stay in the
intensive care unit nor the 7- and 30-days mortalities were affected by amiodarone.
Conclusions: Patients receiving long-term amiodarone treatment after myocardial
infarction had a higher rate of intra-aortic balloon use after cardiac surgery. There
was no increased risk of pulmonary complications, need for pacing, or death.
Amiodarone is the most widely used antiarrhythmic drug, and about2% of patients referred for cardiac surgery are receiving long-termamiodarone therapy.1 This agent has several well-described side-effects that could increase postoperative risk, and concern hasbeen raised in several studies regarding the safety of cardiacsurgery for patients receiving long-term amiodarone. Small series
and case-control studies1-8 have raised concerns about the safety of amiodarone
therapy for patients undergoing cardiac surgery.
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In these reports three adverse effects have been specifi-
cally associated with cardiac surgery in patients receiving
long-term amiodarone therapy: pulmonary complications
related to adult respiratory distress syndrome,2-4,6,7 pro-
longed hypotension related to resistant peripheral vasodila-
tation or low cardiac output,4-9 and bradycardia requiring
pacing.8-10 Although the adverse effects reported may have
been due to amiodarone, the risk of postoperative compli-
cations from amiodarone may have been overestimated be-
cause patients who receive amiodarone often have advanced
heart disease, and none of these studies had proper control
groups. The observed adverse effects thus may have been
related to the severe underlying cardiac disease rather than
to amiodarone therapy itself. Indeed, in one case-control
study1 no significant increase in complications was found in
the amiodarone-treated group relative to the control group
when multivariate analysis was used to account for the
severity of underlying medical conditions. No randomized
controlled data have been reported evaluating the perioper-
ative risk of long-term amiodarone therapy for patients
undergoing cardiac surgery.
The Canadian Amiodarone Myocardial Infarction Ar-
rhythmia Trial (CAMIAT) was a randomized, double-blind,
placebo-controlled trial of amiodarone among survivors of
myocardial infarction at risk for arrhythmic death.11 To
determine whether long-term amiodarone therapy increases
the perioperative risk of cardiac surgery, adverse effect data
related to cardiac surgery were collected prospectively for
patients who participated in CAMIAT. This report com-
pares the risk of postoperative complications related to
cardiac surgery in CAMIAT patients randomly assigned in
a double-blinded fashion to receive either amiodarone or
placebo.
Methods
Eligibility of Patients
The eligibility criteria for CAMIAT have been published previ-
ously elsewhere.11 In brief, patients were eligible if they met the
following criteria: (1) myocardial infarction within the previous 6
to 45 days, (2) 24-hour Holter monitoring showing 10 ventric-
ular premature beats/hour or at least one run of ventricular tachy-
cardia, and (3) age greater than 19 years. The study was approved
by local institutional review boards in all participating centers.
Treatment and Follow-up
Patients received an oral dose of 10 mg/(kg  d) of amiodarone or
placebo for 2 weeks, followed by 400 mg daily, except in those
patients less than 60 kg in weight or older than 75 years, for whom
the dose was reduced to 300 mg daily. Patients were reassessed at
both months 4 and 8 by 24-hour Holter monitor. If arrhythmia
suppression was observed, the dose was further reduced by 100
mg/d to a potential minimum dose of 200 mg/d, or 200 mg/d 5
d/wk for those older than 75 years or less than 60 kg in weight.
Cardiac Surgery in CAMIAT Patients
The CAMIAT protocol specified that study patients who under-
went elective heart surgery should stop study medication 7 days
before the surgical date and that the medication be resumed after
surgery once the patient was hemodynamically stable. Among the
1202 patients participating in the CAMIAT, surgical complication
data were available for 87 patients who underwent cardiac surgery
during the study (7.2%). Among those 87 patients, 5 had had the
study medication permanently discontinued more than 3 months
before the operation, and they were not included in this analysis.
Of the remaining 82 patients, 46 had been randomly assigned to
the placebo group and 36 had been assigned to the amiodarone
group. In the amiodarone treatment group 24 patients were still
receiving active medication within 7 days of surgery (active ami-
odarone group), whereas 12 had discontinued the study medication
at least 7 days before the surgery (discontinued amiodarone
group). The mean maintenance dose of amiodarone (among those
patients who were receiving amiodarone) was 353  84 mg. The
median number of days that amiodarone was stopped before the
surgery (discontinued amiodarone group) was 15 days (interquar-
tile range 11-41 days).
Postoperative Outcome Events in Study Patients
Undergoing Cardiac Surgery
The postoperative period during which the adverse events were
recorded was defined as beginning at the time of exit from the
operating room until postoperative day 7. The total number of days
in the intensive care unit was noted for all patients. Only electro-
cardiographically documented postoperative arrhythmias were in-
cluded. These included asystole of more than 4 seconds, complete
atrioventricular block, new atrial fibrillation (lasting 30 min-
utes), and resuscitated ventricular fibrillation. Postoperative uses
of temporary pacing, counter pulsation intra-aortic balloon pump,
or inotropic drugs were recorded for all patients, and the total time
in hours that such therapies were required was calculated as a
period from the first beginning of the treatment to the last discon-
tinuation. All cardiovascular, pulmonary, and other complications
were recorded. The 7- and 30-day mortalities were recorded.
Statistics
Comparisons among the three groups used the Fisher exact test for
categoric variables and the Kruskal-Wallis test for continuous
variables.
Results
Baseline Characteristics
The baseline demographic and clinical characteristics of the
patients are presented in Table 1. There were no differences
in baseline patient characteristics with regard to mean age;
previous (to index) myocardial infarction; previous history
of pulmonary edema, stroke, chronic respiratory disease, or
diabetes; or previous cardiac surgery. The types of surgical
procedures performed were similar between groups, with
most patients undergoing coronary artery bypass grafting.
There was no difference in the preoperative use of -block-
ers, diltiazem, or verapamil.
Cardiopulmonary Support and Physiology Crystal et al
634 The Journal of Thoracic and Cardiovascular Surgery ● March 2003
CSP
Hospital Course and Complications
The rates of postoperative asystole (Table 2) were similar in
the three study groups: 4.2% of patients in the active ami-
odarone group, 8.3% of patients in the discontinued amio-
darone group, and 4.4% of patients in the placebo group
(P  .79). The incidences of postoperative ventricular fi-
brillation were similar in the three study groups: 4.2% of
patients in the active amiodarone group, 8.3% of patients in
the discontinued amiodarone group, and 13.3% of patients
in the placebo group (P  .6). The incidences of atrial
fibrillation were 16.7% in the active amiodarone group,
16.7% in the discontinued amiodarone group, and 24.8% in
the placebo group (P  .7). The rates for use of temporary
pacing were 26.1% in the active amiodarone group, 25% in
the discontinued amiodarone group, and 10.9% in the pla-
cebo group. The prespecified three-group comparison of
three differences in need for temporary pacing had a P value
of .19; the P value for the comparison of the combined
amiodarone groups against placebo was also firmly nonsig-
nificant at a P value of .14. The mean durations of tempo-
rary pacing were 37.2  30.7 hours, 7.3  6.0 hours and
7.2  6.1 hours for the active amiodarone, discontinued
amiodarone, and placebo groups, respectively (P  .12).
Intra-aortic balloon pumps were used by 10 study centers
in 14 patients. Patients on amiodarone were significantly
more likely to use intra-aortic balloon pump therapy (34.8%
in the active amiodarone group, 16.7% in the discontinued
amiodarone group, and 8.7% in the placebo group, P .03).
The indications for balloon pump therapy were not specif-
ically collected. In terms of duration of the support, the data
from the discontinued amiodarone group (n  2) were
unavailable, but no significant difference was found be-
tween the active amiodarone and placebo groups (93  171
hours in active amiodarone group vs 42  61 hours in
placebo group, P  .67).
The rates of catecholamine drug use were similar in the
three study groups (60.9% in the active amiodarone group,
50.0% in the discontinued amiodarone group, and 43.5% in
the placebo group, P  .37). The duration of inotropic
support was not significantly different among the groups
(P  .31).
Pulmonary complications were infrequent, and their rate
did not differ among the study groups: 0% in the active
amiodarone group, 16% in the discontinued amiodarone
group, and 2% in the placebo group (P  .4).
Mortalities and durations of intensive care unit stay are
shown in Table 3. The mean postoperative intensive care
unit stays were similar in the three study groups: 6.1  9.2
days in the active amiodarone group, 2.8  1.6 days in the
discontinued amiodarone group, and 3.6  3.9 days in the
placebo group (P .41). The 7-day mortality was 0% in the
active amiodarone group, 8.3% in the discontinued amio-
darone group, and 0% in the placebo group (P  .15).
TABLE 1. Baseline demographic and clinical characteristics
Amiodarone (n  36)
Patient characteristics
Active
amiodarone
(n  24)
Discontinued
amiodarone*
(n  12)
Placebo
(n  46) P value†
Age (y, mean  SD) 61.2 9.0 61.4 8.8 58.8 10.4 .523
Multiple myocardial infarctions (No.) 7 (29.2%) 5 (41.7%) 23 (50%) .245
Previous pulmonary edema (No.) 7 (29.2%) 3 (25%) 11 (23.9%) .937
Stroke (No.) 0 0 4 (8.7%) .354
Chronic respiratory disease (No.) 3 (12.5%) 2 (16.7%) 3 (6.5%) .391
Diabetes mellitus (No.) 6 (25.0%) 4 (33.3%) 9 (19.6%) .581
Previous heart surgery (No.) 1 (4.2%) 2 (16.7%) 3 (6.5%) .340
Type of index cardiac surgery (No.)
Coronary artery bypass grafting 24 (100.0%) 12 (100.0%) 45 (97.8%) .999
Aortic valve replacement 0 1 (8.3%) 1 (2.2%) .356
Mitral valve replacement 0 0 2 (4.4%) .668
Aneurysm resection 1 (4.2%) 1 (8.3%) 5 (10.9%) .858
Other 0 1 (9.1%) 2 (4.4%) .242
Medications within 24 hours (No.)
Verapamil 1 (5.6%) 0 1 (2.7%) .999
Diltiazem 6 (33.3%) 3 (42.9%) 13 (35.1%) .861
-Blocker 12 (66.7%) 5 (71.4%) 28 (75.7%) .772
Time between random assignment
and heart surgery (d, median and
interquartile range)
90 (21-116) 164 (97-306) 154 (47-244) .063
*Amiodarone stopped 7 days before surgery per CAMIAT protocol.
†P value for comparison of three groups.
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Thirty-day mortality rates were 4.2%, 8.3% and 2.2%, re-
spectively (P  .55).
Discussion
These results from a randomized, double-blind, placebo-
controlled trial support earlier observations that long-term
amiodarone therapy increases postoperative risk of pro-
longed systemic hypotension requiring placement of an
intra-aortic balloon pump. Unlike many previous reports, no
significant increases were seen in risk of pulmonary com-
plications or in bradycardia requiring pacing. Discontinua-
tion of amiodarone treatment for about a week before the
operation may decrease the risk of amiodarone-associated
hypotension and the need for intra-aortic balloon pump
placement.
The intra-aortic balloon pump is used to increase cardiac
output and to manage systemic hypotension. Intractable
vasodilatation leading to prolonged hypotension, with or
without low cardiac output, has been previously reported
postoperatively in patients receiving long-term amiodarone
therapy.1,8,9,12 This is probably due to accentuation of one of
amiodarone’s known pharmacologic actions, sympathetic
system blockade, which may result in profound vasodilata-
tion.9,12 The use of vasopressor drugs in this study was
somewhat more frequent among patients receiving amioda-
rone than those receiving placebo, but the difference were
not statistically significant. The observed use of intra-aortic
balloon pumping with amiodarone may be depend on si-
multaneous treatment with other drugs, such as -blockers
and angiotensin-converting enzyme inhibitors, which poten-
tially depress the available compensatory mechanisms.12
Amiodarone is known to cause depression of sinus and
atrioventricular node automaticity and conduction, and an
increased use of perioperative pacemaker therapy in patients
receiving amiodarone has been previously reported.8-10 The
study groups were well balanced in the use of other drugs
TABLE 2. Postoperative complications
Complications
Amiodarone (n  36)
Active
amiodarone*
(n  24)
Discontinued
amiodarone
(n  12*)
Placebo
(n  46) P value
Arrhythmia
Asystole  4 s (No.) 1 (4.2) 1 (8.3) 2 (4.4%) .8
Ventricular fibrillation (No.) 1 (4.2) 1 (8.3) 6 (13.3%) .6
New atrial fibrillation (No.) 4 (16.7) 2 (16.7) 11 (24.8%) .7
Temporary pacing need (No.) 6 (26.1) 3 (25.0) 5 (10.9%) .19
Mean duration of temporary
postoperative pacing (h, mean  SD)
37.2 30.7 7.3 6.0 7.2 6.1 .117†
Hemodynamic instability
Need for balloon pump (No.) 8 (34.8) 2 (16.7) 4 (8.7%) .027
Duration of pump support (h,
mean SD)
93.1 171.0 — 32.5 43.2 .669†
Need for inotropic drugs (No.) 14 (60.9) 6 (50.0) 20 (43.5%) .371
Duration of inotropic drug support
(h, mean  SD)
136.8 195.1 30.3 34.4 42.4 61.4 .314†
Pulmonary complications (No.) 0 2 (16.6) 1 (2.2%) .4
*Amiodarone stopped 7 days before surgery per CAMIAT protocol.
†Nonparametric value.
TABLE 3. Postoperative intensive care unit stay and mortality
Amiodarone (n  36)
Active
amiodarone
(n  24)
Discontinued
amiodarone*
(n  12)
Placebo
(n  46) P value
Postoperative intensive
care unit stay
(d, mean  SD)
6.1 9.2 2.8 1.6 3.6 3.9 .412
7-d mortality 0% 8.3% 0% .146
30-d mortality 4.2% 8.3% 2.2% .548
*Amiodarone stopped 7 days before surgery per CAMIAT protocol.
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that affect the cardiac conduction system, such as -block-
ers and calcium-channel blockers (Table 1). It appears that
the bradycardia caused by amiodarone is not worsened in
the perioperative state.
Long-term amiodarone therapy can cause a pulmonary
interstitial infiltrate during.13 An acute adult respiratory
distress syndrome occurring in immediate postoperative pe-
riod has been attributed to amiodarone.2-7 On the other
hand, some studies1,8 reported no significant increase in
postoperative pulmonary complications among patients re-
ceiving long-term amiodarone therapy. Previous studies
have varied widely in their estimates of the relative risk of
development of adult respiratory distress syndrome with
amiodarone, from no increase1 to a 5-fold increase.4 In our
study the risk of postoperative respiratory complications
was small in all groups and was not increased by the
long-term use of amiodarone. This finding suggests that the
risk of amiodarone-induced pulmonary complications was
overestimated in these previous nonrandomized reports.
The observed rate of postoperative atrial fibrillation was
lower among patients receiving amiodarone, but the differ-
ence was not statistically significant (Table 2). Several
studies have reported that amiodarone reduces atrial fibril-
lation both during long-term follow-up and when used pro-
phylactically after heart surgery.14 It is likely that the rela-
tively small number of patients in this analysis rendered it
underpowered to detect a true difference.
Discontinuation of amiodarone before cardiac surgery
for the median period of 2 weeks was associated with a
reduction in amiodarone-associated increased need for in-
tra-aortic balloon pumping. It was also associated with a
trend toward a shorter period of temporary pacing. Although
the CAMIAT protocol specified withdrawal of study drug 7
days before elective surgery, the actual decision to withdraw
the drug was made by the investigators. Because amioda-
rone withdrawal before surgery was not randomly deter-
mined, differences between patients who had amiodarone
withdrawn and those who did not may be due to patient
selection. Nonetheless, the data from the analysis support
the concept of withdrawing amiodarone when possible for a
week before surgery.
Limitations
A main limitation of this study is the low number of the
patients involved and the low frequency of events. Another
limitation is that detailed hemodynamic data were not col-
lected during the perioperative period. The cardiac status of
the involved patients in this study may have been better than
that of patients receiving long-term amiodarone therapy for
treatment of cardiac arrhythmia.
References
1. Rady MY, Ryan T, Starr NJ. Preoperative therapy with amiodarone
and the incidence of acute organ dysfunction after cardiac surgery.
Anesth Analg. 1997;85:489-97.
2. Nalos PC, Kass RM, Gang ES, Fishbein MC, Mandel WJ, Peter T.
Life-threatening postoperative pulmonary complications in patients
with previous amiodarone pulmonary toxicity undergoing cardiotho-
racic operations. J Thorac Cardiovasc Surg. 1987;93:904-12.
3. Tuzcu EM, Maloney JD, Sangani BH, Masterson ML, Hocevar KD,
Golding LA, et al. Cardiopulmonary effects of chronic amiodarone
therapy in the early postoperative course of cardiac surgery patients.
Cleve Clin J Med. 1987;54:491-7.
4. Kupferschmid JP, Rosengart TK, McIntosh CL, Leon MB, Clark RE.
Amiodarone-induced complications after cardiac operation for ob-
structive hypertrophic cardiomyopathy. Ann Thorac Surg. 1989;48:
359-64.
5. Greenspon AJ, Kidwell GA, Hurley W, Mannion J. Amiodarone-
related postoperative adult respiratory distress syndrome. Circulation.
1991;84(5 suppl):III407-15.
6. Hawthorne HR, Wood MA, Stambler BS, Damiano RJ, Ellenbogen
KA. Can amiodarone pulmonary toxicity be predicted in patients
undergoing implantable cardioverter defibrillator implantation? Pac-
ing Clin Electrophysiol. 1993;16:2241-9.
7. Mickleborough LL, Maruyama H, Mohamed S, Rappaport DC, Dow-
nar E, Butany J, et al. Are patients receiving amiodarone at increased
risk for cardiac operations? Ann Thorac Surg. 1994;58:622-9.
8. Dimopoulou I, Marathias K, Daganou M, Prapas S, Stavridis G,
Khoury M, et al. Low-dose amiodarone-related complications after
cardiac operations. J Thorac Cardiovasc Surg. 1997;114:31-7.
9. Liberman BA, Teasdale SJ. Anaesthesia and amiodarone. Can An-
aesth Soc J. 1985;32:629-38.
10. Terada Y, Mitsui T, Yamaguchi I. Conduction disturbances after open
heart operation in a patient receiving amiodarone. Ann Thorac Surg.
1994;58:1213-4.
11. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of
outcome after myocardial infarction in patients with frequent or re-
petitive ventricular premature depolarisations: CAMIAT. Canadian
Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.
Lancet. 1997;349:675-82.
12. Mets B, Michler RE, Delphin ED, Oz MC, Landry DW. Refractory
vasodilation after cardiopulmonary bypass for heart transplantation in
recipients on combined amiodarone and angiotensin- converting en-
zyme inhibitor therapy: a role for vasopressin administration. J Car-
diothorac Vasc Anesth. 1998;12:326-9.
13. Jessurun GA, Boersma WG, Crijns HJ. Amiodarone-induced pulmo-
nary toxicity. Predisposing factors, clinical symptoms and treatment.
Drug Saf. 1998;18:339-44.
14. Bharucha DB, Kowey PR. Management and prevention of atrial
fibrillation after cardiovascular surgery. Am J Cardiol. 2000;85(10
Suppl 1):20-4.
Crystal et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 3 637
CS
P
